Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print   

Friday 11 March, 2022

Omega Diagnostics Gp

Update on validation under CTDA legislation

RNS Number : 4089E
Omega Diagnostics Group PLC
11 March 2022
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Update on validation under CTDA legislation

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, has been informed by the UK Health Security Agency that the application for approval of the professional-use VISITECT® COVID-19 Antigen test under the Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 ("CTDA") has been unsuccessful, and accordingly the product will not be available for sale in the general UK market.

 

Some supporting data provided by third-party development partners and submitted for the Desktop Review used comparator RT-qPCR (Quantitative reverse transcription PCR) results from studies conducted in late 2020 and early 2021 and pre-date the CTDA regulations.  Certain of these comparator tests were not CE-marked and/or did not meet the sensitivity/specificity requirements subsequently specified in the CTDA regulations.  These results therefore had to be excluded from the review and, as a consequence, there are now insufficient test results to meet the CTDA requirements.  Currently, with insufficient demand for the professional-use test, the Company does not plan to commission further studies at this time. 

 

The Directors believe that the self-test market is much more relevant in terms of opportunity and Omega continues to work closely with its external study centres to ensure the 31 March 2022 deadline is met for the submission of the outstanding self-test CE Mark data.

 

Jag Grewal, CEO of Omega, commented:  "Whilst this is clearly disappointing, our plans do not include any contribution from COVID-19 antigen tests, as we focus the business on driving growth in our Health & Nutrition division."

 

Contacts: 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer

 

 

 

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

 

Alice Lane/ Charlotte Sutcliffe (ECM)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

       

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFUFMSEESEDD

a d v e r t i s e m e n t